Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 96

1.

Molecular imaging of EGFR/HER2 cancer biomarkers by protein MRI contrast agents.

Qiao J, Xue S, Pu F, White N, Jiang J, Liu ZR, Yang JJ.

J Biol Inorg Chem. 2014 Feb;19(2):259-70. doi: 10.1007/s00775-013-1076-3. Epub 2013 Dec 24. Review.

2.

HER2 targeted molecular MR imaging using a de novo designed protein contrast agent.

Qiao J, Li S, Wei L, Jiang J, Long R, Mao H, Wei L, Wang L, Yang H, Grossniklaus HE, Liu ZR, Yang JJ.

PLoS One. 2011 Mar 24;6(3):e18103. doi: 10.1371/journal.pone.0018103.

3.

Design of a novel class of protein-based magnetic resonance imaging contrast agents for the molecular imaging of cancer biomarkers.

Xue S, Qiao J, Pu F, Cameron M, Yang JJ.

Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2013 Mar-Apr;5(2):163-79. doi: 10.1002/wnan.1205. Epub 2013 Jan 17. Review.

4.

Tumor detection using magnetosome nanoparticles functionalized with a newly screened EGFR/HER2 targeting peptide.

Xiang Z, Yang X, Xu J, Lai W, Wang Z, Hu Z, Tian J, Geng L, Fang Q.

Biomaterials. 2017 Jan;115:53-64. doi: 10.1016/j.biomaterials.2016.11.022. Epub 2016 Nov 16.

PMID:
27888699
5.

Bispecific Antibody Conjugated Manganese-Based Magnetic Engineered Iron Oxide for Imaging of HER2/neu- and EGFR-Expressing Tumors.

Wu SC, Chen YJ, Wang HC, Chou MY, Chang TY, Yuan SS, Chen CY, Hou MF, Hsu JT, Wang YM.

Theranostics. 2016 Jan 1;6(1):118-30. doi: 10.7150/thno.13069. eCollection 2016.

6.

Magnetic resonance in the era of molecular imaging of cancer.

Gore JC, Manning HC, Quarles CC, Waddell KW, Yankeelov TE.

Magn Reson Imaging. 2011 Jun;29(5):587-600. doi: 10.1016/j.mri.2011.02.003. Epub 2011 Apr 27. Review.

7.

HER2+ Cancer Cell Dependence on PI3K vs. MAPK Signaling Axes Is Determined by Expression of EGFR, ERBB3 and CDKN1B.

Kirouac DC, Du J, Lahdenranta J, Onsum MD, Nielsen UB, Schoeberl B, McDonagh CF.

PLoS Comput Biol. 2016 Apr 1;12(4):e1004827. doi: 10.1371/journal.pcbi.1004827. eCollection 2016 Apr.

8.

An heregulin-EGFR-HER3 autocrine signaling axis can mediate acquired lapatinib resistance in HER2+ breast cancer models.

Xia W, Petricoin EF 3rd, Zhao S, Liu L, Osada T, Cheng Q, Wulfkuhle JD, Gwin WR, Yang X, Gallagher RI, Bacus S, Lyerly HK, Spector NL.

Breast Cancer Res. 2013;15(5):R85.

9.

GRPR-targeted Protein Contrast Agents for Molecular Imaging of Receptor Expression in Cancers by MRI.

Pu F, Qiao J, Xue S, Yang H, Patel A, Wei L, Hekmatyar K, Salarian M, Grossniklaus HE, Liu ZR, Yang JJ.

Sci Rep. 2015 Nov 18;5:16214. doi: 10.1038/srep16214.

10.

Design of ProCAs (protein-based Gd(3+) MRI contrast agents) with high dose efficiency and capability for molecular imaging of cancer biomarkers.

Xue S, Qiao J, Jiang J, Hubbard K, White N, Wei L, Li S, Liu ZR, Yang JJ.

Med Res Rev. 2014 Sep;34(5):1070-99. doi: 10.1002/med.21313. Epub 2014 Mar 11. Review.

PMID:
24615853
11.
12.

Chemistry of tumour targeted T1 based MRI contrast agents.

Kamaly N, Miller AD, Bell JD.

Curr Top Med Chem. 2010;10(12):1158-83. Review.

PMID:
20388110
13.

MRI virtual biopsy and treatment of brain metastatic tumors with targeted nanobioconjugates: nanoclinic in the brain.

Patil R, Ljubimov AV, Gangalum PR, Ding H, Portilla-Arias J, Wagner S, Inoue S, Konda B, Rekechenetskiy A, Chesnokova A, Markman JL, Ljubimov VA, Li D, Prasad RS, Black KL, Holler E, Ljubimova JY.

ACS Nano. 2015 May 26;9(5):5594-608. doi: 10.1021/acsnano.5b01872. Epub 2015 May 6.

14.

Subtype classification for prediction of prognosis of breast cancer from a biomarker panel: correlations and indications.

Chen C, Yuan JP, Wei W, Tu Y, Yao F, Yang XQ, Sun JZ, Sun SR, Li Y.

Int J Nanomedicine. 2014 Feb 21;9:1039-48. doi: 10.2147/IJN.S58270. eCollection 2014.

15.

Current limitations of molecular magnetic resonance imaging for tumors as evaluated with high-relaxivity CD105-specific iron oxide nanoparticles.

Dassler K, Roohi F, Lohrke J, Ide A, Remmele S, Hütter J, Pietsch H, Pison U, Schütz G.

Invest Radiol. 2012 Jul;47(7):383-91. doi: 10.1097/RLI.0b013e31824c5a57.

PMID:
22659596
16.

Perspectives on Epidermal Growth Factor Receptor Regulation in Triple-Negative Breast Cancer: Ligand-Mediated Mechanisms of Receptor Regulation and Potential for Clinical Targeting.

Williams CB, Soloff AC, Ethier SP, Yeh ES.

Adv Cancer Res. 2015;127:253-81. doi: 10.1016/bs.acr.2015.04.008. Epub 2015 May 8. Review.

PMID:
26093903
17.
18.

Biomarkers of drugs targeting HER-family signalling in cancer.

Montemurro F, Scaltriti M.

J Pathol. 2014 Jan;232(2):219-29. doi: 10.1002/path.4269. Review.

PMID:
24105684
19.

Differential spatial expression and activation pattern of EGFR and HER2 in human breast cancer.

Fink-Retter A, Gschwantler-Kaulich D, Hudelist G, Mueller R, Kubista E, Czerwenka K, Singer CF.

Oncol Rep. 2007 Aug;18(2):299-304.

PMID:
17611648
20.

AZD8931, an equipotent, reversible inhibitor of signaling by epidermal growth factor receptor (EGFR), HER2, and HER3: preclinical activity in HER2 non-amplified inflammatory breast cancer models.

Mu Z, Klinowska T, Dong X, Foster E, Womack C, Fernandez SV, Cristofanilli M.

J Exp Clin Cancer Res. 2014 May 30;33:47. doi: 10.1186/1756-9966-33-47.

Supplemental Content

Support Center